Abstract
Objective We identified factors influencing outcomes in patients with medically inoperable early‐stage lung cancer (MIESLC) treated with stereotactic ablative radiation therapy (SABR) at 14 centers in Turkey. Methods We retrospectively analyzed 431 patients with stage I‐II MIESLC treated with SABR from 2009 through 2017. Age; sex; performance score; imaging technique; tumor histology and size; disease stage radiation dose, fraction, and biologically effective dose with an α/β ratio of 10 (BED10); tumor location; and treatment center were evaluated for associations with overall survival (OS), local control (LC), and toxicity. Results Median follow‐up time was 27 months (range 1–115); median SABR dose was 54Gy (range 30–70) given in a median 3 fractions (range 1–10); median BED10 was151 Gy (range 48–180). Tumors were peripheral in 285 patients (66.1%), central in 69 (16%), and 100Gy (p =0.011), adenocarcinoma (p =0.025), and complete response on first evaluation (p =0.007) predicted favorable LC. BED10>120Gy (hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.1–3.2,p =0.019) and tumor size (p =0.003) predicted favorable OS. No grade 4‐5 acute side effects were observed; late effects were grade ≤3 pneumonitis (18 [4.2%]), chest wall pain (11 [2.5%]), and rib fracture (1 [0.2%]). Conclusion SABR produced encouraging results, with satisfactory LC and OS and minimal toxicity. BED10>120 Gy was needed for better LC and OS for large, non‐adenocarcinoma tumors.

This publication has 31 references indexed in Scilit: